Xencor (XNCR) Total Current Liabilities (2013 - 2026)
Xencor's (XNCR) quarterly Total Current Liabilities came in at $73.5 million in Q1 2026, down 16.94% year-on-year from $88.4 million in Q1 2025, and down 23.41% on a QoQ basis from $95.9 million in Q4 2025.
Xencor (XNCR) Total Current Liabilities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Total Current Liabilities data on file, last reported at $73.5 million in Q1 2026.
- On a quarterly basis, Total Current Liabilities fell 16.94% year-over-year to $73.5 million in Q1 2026; TTM through Mar 2026 was $73.5 million, a 16.94% decrease from a year earlier, with the FY2025 full-year figure at $95.9 million, up 9.69% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $73.5 million, down from $95.9 million in the prior quarter.
- Over the last five years, Total Current Liabilities for XNCR reached as high as $96.1 million in Q2 2025 and fell as low as $44.6 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $76.0 million across 5 years, with a median of $75.0 million in 2022.
- Across the five-year window, Total Current Liabilities jumped 103.15% in 2022 and plunged 41.09% in 2023, its largest moves.
- Year by year, Total Current Liabilities stood at $63.8 million in 2022, then grew by 15.77% to $73.9 million in 2023, then grew by 18.29% to $87.4 million in 2024, then grew by 9.69% to $95.9 million in 2025, then fell by 23.41% to $73.5 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $73.5 million in Q1 2026, $95.9 million in Q4 2025, and $86.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | 73.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.46 Mn |
| Dec 31, 2025 | 95.91 Mn |
| Sep 30, 2025 | 86.49 Mn |
| Jun 30, 2025 | 96.08 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Dec 31, 2024 | 87.43 Mn |
| Sep 30, 2024 | 90.81 Mn |
| Jun 30, 2024 | 75.59 Mn |
| Mar 31, 2024 | 71.08 Mn |
| Dec 31, 2023 | 73.92 Mn |
| Sep 30, 2023 | 53.04 Mn |
| Jun 30, 2023 | 44.63 Mn |
| Mar 31, 2023 | 65.06 Mn |
| Dec 31, 2022 | 63.84 Mn |
| Sep 30, 2022 | 90.03 Mn |
| Jun 30, 2022 | 75.04 Mn |
| Mar 31, 2022 | 60.94 Mn |
| Dec 31, 2021 | 70.74 Mn |
| Sep 30, 2021 | 44.32 Mn |
| Jun 30, 2021 | 45.96 Mn |